You may find more results for this query on our sister sites: GenomeWeb and Precision Oncology News.
The firms have eliminated several terms of their original deal and have cross-licensed IP to allow Med BioGene to license Gene FX Lung to other firms.
The deal gives Bio-Rad licensing rights to a PCR-based platform and an assay that improves diagnostic sensitivity and efficacy across four dengue serotypes.
The technology is used in Qiagen's newly CE-marked test for cervical cancer and is complementary to human papillomavirus screening tests.
